Literature DB >> 27910703

Co-calibration of two self-reported measures of adherence to antiretroviral therapy.

Robin M Nance1, J A Chris Delaney2, Carol E Golin3, Wendee M Wechsberg4, Chinazo Cunningham5, Frederick Altice6, Katerina Christopoulos7, Kevin Knight8, Vu Quan9, Michael S Gordon10, Sandra Springer11, Jeremy Young12, Paul K Crane1, Kenneth H Mayer13, Michael J Mugavero14, Carlos Del Rio15, Richard A Kronmal2, Heidi M Crane1.   

Abstract

Adherence to antiretroviral therapy (ART) is an important determinant of clinical success assessed in many HIV studies. Harmonizing adherence data from studies that use different measures is difficult without a co-calibration equation to convert between validated instruments. Our purpose was to co-calibrate two commonly used adherence measures: the AIDS Clinical Trials Group (ACTG) questionnaire and the Visual Analog Scale (VAS). We used robust linear regression to develop a co-calibration equation in a clinical care cohort. The outcome was the 30-day VAS percentage of ART taken and the predictors were ACTG questions. We evaluated the equation's goodness of fit in five STTR (Seek, Test, Treat, Retain) consortium studies where individuals completed both measures: 2 criminal justice; 2 international; and 1 other high-risk vulnerable population. We developed a three-phase decision rule to convert ACTG to VAS in 1045 participants. First, when the last missed dose on the ACTG was reported as >30 days ago, the VAS was set to 100% (N = 582). Second, if "doses missed" was zero for all items, VAS was 100% (N = 104). Third, among remaining participants (N = 359), VAS was estimated as 96.8% minus 2.9% times the number of missed doses ("doses per day" was non-significant). Correlation between predicted and reported VAS was r = 0.80 in the criminal justice group (N = 446), r = 0.46 in the international group (N = 311), r = 0.32 in the other vulnerable population (N = 63), and r = 0.66 overall. When outliers due to inversion of the VAS scale were excluded (n = 25), these correlations were 0.88, 0.78, 0.80, and 0.86, respectively. We concluded that a simple decision rule and equation allowed us to co-calibrate between two widely used adherence measures thus combining data from studies with different instruments. This study highlighted issues with VAS inversions and its limitations as a single item. Combining studies using different instrument facilitates larger pooled datasets to address key research questions.

Entities:  

Keywords:  Adherence; HIV; antiretroviral therapy; calibration; visual analog scale

Mesh:

Substances:

Year:  2016        PMID: 27910703      PMCID: PMC5291764          DOI: 10.1080/09540121.2016.1263721

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  11 in total

1.  Data Collection and Harmonization in HIV Research: The Seek, Test, Treat, and Retain Initiative at the National Institute on Drug Abuse.

Authors:  Redonna K Chandler; Shoshana Y Kahana; Bennett Fletcher; Dionne Jones; Matthew S Finger; Will M Aklin; Kathleen Hamill; Candace Webb
Journal:  Am J Public Health       Date:  2015-10-15       Impact factor: 9.308

Review 2.  Self-report measures of medication adherence behavior: recommendations on optimal use.

Authors:  Michael J Stirratt; Jacqueline Dunbar-Jacob; Heidi M Crane; Jane M Simoni; Susan Czajkowski; Marisa E Hilliard; James E Aikens; Christine M Hunter; Dawn I Velligan; Kristen Huntley; Gbenga Ogedegbe; Cynthia S Rand; Eleanor Schron; Wendy J Nilsen
Journal:  Transl Behav Med       Date:  2015-07-09       Impact factor: 3.046

3.  Monitoring adherence to HIV antiretroviral therapy in routine clinical practice: The past, the present, and the future.

Authors:  David R Bangsberg
Journal:  AIDS Behav       Date:  2006-05

Review 4.  Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management.

Authors:  Jane M Simoni; Ann E Kurth; Cynthia R Pearson; David W Pantalone; Joseph O Merrill; Pamela A Frick
Journal:  AIDS Behav       Date:  2006-05

5.  "In their perception we are addicts": social vulnerabilities and sources of support for men released from drug treatment centers in Vietnam.

Authors:  Cecilia Tomori; Vivian F Go; Le Nhan Tuan; Nguyen Mai Huong; Nguyen Thanh Binh; Carla E Zelaya; David D Celentano; Do Tuan Dat; Vu Minh Quan
Journal:  Int J Drug Policy       Date:  2014-04-28

6.  Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).

Authors:  M A Chesney; J R Ickovics; D B Chambers; A L Gifford; J Neidig; B Zwickl; A W Wu
Journal:  AIDS Care       Date:  2000-06

7.  Rapid HIV testing for individuals on probation/parole: outcomes of an intervention trial.

Authors:  Michael S Gordon; Timothy W Kinlock; Michelle McKenzie; Monique E Wilson; Josiah D Rich
Journal:  AIDS Behav       Date:  2013-07

8.  Characteristics of methadone maintenance treatment patients prescribed opioid analgesics.

Authors:  Matthew C Glenn; Nancy L Sohler; Joanna L Starrels; Jeronimo Maradiaga; John J Jost; Julia H Arnsten; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2016-01-05       Impact factor: 3.716

9.  Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems.

Authors:  Mari M Kitahata; Benigno Rodriguez; Richard Haubrich; Stephen Boswell; W Christopher Mathews; Michael M Lederman; William B Lober; Stephen E Van Rompaey; Heidi M Crane; Richard D Moore; Michael Bertram; James O Kahn; Michael S Saag
Journal:  Int J Epidemiol       Date:  2008-02-08       Impact factor: 7.196

10.  The biobehavioral Women's Health CoOp in Pretoria, South Africa: study protocol for a cluster-randomized design.

Authors:  Wendee M Wechsberg; William A Zule; Jacqueline Ndirangu; Tracy L Kline; Nathaniel F Rodman; Irene A Doherty; Scott P Novak; Charles M van der Horst
Journal:  BMC Public Health       Date:  2014-10-15       Impact factor: 3.295

View more
  3 in total

1.  Short Communication: Bioequivalence of Tenofovir Component of Tenofovir/Rilpivirine/Emtricitabine in Digital Pills.

Authors:  Peter R Chai; Luis M Pereira; Guruprasad D Jambaulikar; Adam W Carrico; Conall O'Cleirigh; Kenneth H Mayer; Edward W Boyer
Journal:  AIDS Res Hum Retroviruses       Date:  2019-03-13       Impact factor: 2.205

2.  The PROSPER-HIV Study: A Research Protocol to Examine Relationships Among Physical Activity, Diet Intake, and Symptoms in Adults Living With HIV.

Authors:  Allison R Webel; Dustin Long; Benigno Rodriguez; Christine Horvat Davey; Thomas W Buford; Heidi M Crane; Kenneth Mayer; Michael S Saag; Amanda L Willig
Journal:  J Assoc Nurses AIDS Care       Date:  2020 May-Jun       Impact factor: 1.354

3.  Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial.

Authors:  Adriana Ammassari; Wolfgang Stöhr; Andrea Antinori; Jean-Michel Molina; Christine Schwimmer; Pere Domingo; Anders Thalme; Massimo Di Pietro; Cedrick Wallet; Anton Pozniak; Laura Richert; François Raffi
Journal:  J Acquir Immune Defic Syndr       Date:  2018-12-01       Impact factor: 3.731

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.